Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Prime Therapeutics appoints Ellyn Hosch as chief information officer

April 3, 2013

ST. PAUL, Minn., April 3, 2013 /PRNewswire/ — Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), announced today that it has promoted Ellyn Hosch to chief information officer (CIO).

“Ellyn’s industry experience, combined with her knowledge of Prime and clear vision for our future, will support the company’s significant growth,” said Eric Elliott, president and CEO at Prime Therapeutics.

Hosch joined Prime in 2008 as vice president of application development and support. In that role, she led insourcing of Prime’s claims processing system, RxCLAIM, which was successfully completed in 2011. She has also been instrumental in shaping and implementing the strategy for improving internal IT development and support processes to ensure application stability and availability. Over the last five years, Ellyn has progressively increased her scope of responsibility and contribution to Prime.

Prior to joining Prime, Hosch held leadership roles at Diversified Pharmaceutical Services, HealthPartners and UnitedHealth Group.

She has a Masters of Business Administration from the University of St. Thomas and an undergraduate degree from the University of Minnesota.

About Prime Therapeutics
Prime Therapeutics (Prime) helps people get the medicine they need to feel better and live well. Prime offers coverage for medications to health insurers, employers, seniors on Medicare and individuals. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves nearly 20 million people. It is owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.

For more information, visit www.primetherapeutics.com or follow @Prime_PBM on Twitter.

SOURCE Prime Therapeutics


Source: PR Newswire